













The epidemic of chronic kidney disease
Chronic kidney disease (CKD) is increasingly being
acknowledged as a worldwide public health problem
which leads to progressive renal failure, cardiovascular
disease and premature death.1,2 The Third National
Health and Nutrition Examination Surveys (NHANES
III) in the USA found that an estimated 20 million
Americans have CKD.3 It is among the leading causes
of death in the industrialised world, and the 9th most
important cause of death in the USA. Even those
patients who do not progress to end-stage renal disease
(ESRD) requiring dialysis or transplantation have an
increased risk of death from heart and cerebrovascular
disease from any cause.4 The presence of CKD, whether
it is manifested by proteinuria or reduced glomerular
filtration rate (GFR), is now acknowledged as an
independent risk factor for cardiovascular disease
events (CVD) in the most recent report from the Joint
National Committee on Prevention, Detection, and
Treatment of High Blood Pressure (JNC VII) and in a
position statement of the American Heart
Association.5,6 Patients with CKD are considered to be
in the highest-risk group by JNC VII and the US
National Kidney Foundation, with JNC VII including
CKD as a ‘compelling’ indication for optimal blood
pressure control, justifying lower target blood pressure
and treatment with specific antihypertensive agents.
Worldwide there are well over 1 million people on
maintenance dialysis today, and this number is
projected to reach 2 million by 2010. In the USA, over
370 000 are on treatment for ESRD, and this number is
projected to exceed 600 000 by 2010.7 Over 6% of the
US Medicare budget is spent on ESRD.8 Based on the
US average of $66 000 per patient per annum, it is
estimated that 1 trillion dollars would be needed to care
for ESRD patients worldwide from 2001 to 2010.7 In
South Africa, no current information is available on the
numbers or the outcomes of patients with CKD or
ESRD. However, the SA Dialysis and Transplant
Registry is being re-launched by the South African
Renal Society and their initial reports should be
released in the first half of 2006.
Diabetic nephropathy is one of the leading causes of
CKD and ESRD, and the global epidemic of obesity and
type 2 diabetes will therefore result in millions of new
cases of CKD. What is of particular concern is that most
of these cases will be from the developing world, where
there are usually scant resources available to deal with
the problem.9 It is therefore imperative that the focus be
turned to the prevention of CKD, and the slowing of the
progression of the early stages of CKD to ESRD with its
serious and costly complications.
There is convincing evidence that the adverse
complications of CKD can be prevented or delayed by
effective treatment of the earlier stages of CKD, using
strategies which include (among others) good blood
pressure control and blockade of the renin angiotensin
system.10,11 However, there is much variability in the
translation of research findings to improvements in
clinical practice. The successful implementation of
rigorously developed evidence-based clinical practice
guidelines offers a way of reducing this variability of
care and improving patient outcomes.
Differences in renal patient survival in different
countries came to the fore in 1989 at the Dallas
symposium on morbidity and mortality of dialysis
patients, with the USA recording the highest all-cause
annual mortality (22 - 24%).12 For a patient with CKD in
the USA, the outcome is worse than for an equivalent
patient with a diagnosis of colon or prostate cancer.13 It
is thought that differences in practice patterns may be
responsible for these differences in outcomes. The
Third National Health and Nutrition Examination
Surveys (NHANES III) in the USA revealed that only
27% of patients with CKD had a blood pressure 
< 140/90 mmHg, and a majority of patients had severe
anaemia (mean haematocrit 27.7%), with only one
quarter being prescribed erythropoietin despite
insurance cover being available for most of them.
Despite the clear benefits of renal transplantation, most
eligible patients had not been placed on a transplant
waiting list 6 months after beginning dialysis. Lastly,
more than 50% of patients on the US ESRD programme
are malnourished.13
While we lack good data for South Africa, there is no
reason to believe that we do not have similar problems,
with failure to reach therapeutic targets and lack of
awareness of clinical practice guidelines or guidelines
not being effectively implemented.14
The first clinical practice guidelines in nephrology were
developed in 1993 and dealt with the measurement of
the dose of haemodialysis.15 In 1995 the US National
Kidney Foundation (NKF) launched its Dialysis
Outcomes Quality Initiative (DOQI), focusing on the



























adequacy of haemodialysis and peritoneal dialysis,
vascular access and anaemia management.16 These
guidelines changed clinical practice patterns and
impacted favourably on the quality of care.17 In 1999 a
new initiative was launched by the NKF – the Kidney
Disease Outcomes Initiative (K/DOQI) broadened the
scope of the earlier project to include all patients with
kidney disease, from the earliest stages of kidney
damage to end-stage kidney failure requiring dialysis
and transplantation.  The European Renal Association-
European Dialysis and Transplantation Association
have produced the European Best Practice Guidelines
(EBPG), and clinical practice guidelines have also been
developed by the Canadian Society of Nephrology, the
United Kingdom Renal Association, and the Australian
and New Zealand Society of Nephrology.1
While there may be regional differences in risk factors
and in available resources, the complications and
problems of patients with kidney disease are universal
and so is the science and evidence-based approach to
these problems. It has therefore become clear that a
uniform and global approach to developing and
implementing clinical practice guidelines is required.
To this end a new global organisation, Kidney Disease:
Improving Global Outcomes (KDIGO), has been formed
in an attempt to ‘improve the care and outcomes of
kidney disease patients worldwide through promoting
coordination, collaboration, and integration of
initiatives to develop and implement clinical practice
guidelines’.1 The KDIGO Board of Directors includes
world leaders in nephrology, with representation from
North and South America, Europe, Africa and the Far
East. Different work groups will focus on (i) a uniform
system of evidence rating; (ii) the adoption of a
common evaluation, classification and nomenclature for
CKD worldwide; (iii) the establishment of a database of
currently available guidelines; (iv) the implementation
of guidelines; (v) development efforts in regions without
guidelines; (vi) fostering co-ordination between K/DOQI
and EBPG; and (vii) bone and mineral metabolism. 
A standardised and universally accepted scheme for
the detection and classification of CKD will do much to
raise awareness of this important problem, and is
essential for the international development and
implementation of clinical practice guidelines. As one
of their first projects, KDIGO recently completed a
worldwide survey, then sponsored a controversies
conference, which led to the publication of a position
paper on the definition and classification of chronic
kidney disease.18 In essence, the K/DOQI definition and
classification were accepted, with clarifications. CKD is
defined as kidney damage or a glomerular filtration rate
(GFR) of < 60 ml/min/1.73 m2 for 3 months or more,
irrespective of the cause. Kidney damage may be
indicated by the presence of albuminuria (albumin:
creatinine ratio > 30 mg/g) on random urine specimens,
while GFR should be estimated from serum creatinine
using prediction equations such as the Cockcroft Gault
formula or the Modification of Diet in Renal Disease
(MDRD) equation. The diagnosis of CKD does not
require 24-hour urine collections for creatinine
clearance or protein quantification.
Restriction of dietary protein slows the progression of
CKD in animals, but this has been difficult to
demonstrate in humans, and remains the subject of
controversy. A meta-analysis of 13 randomised and 11
non-randomised trials found only a modest benefit from
protein restriction, and similar results were obtained
from the MDRD study, the largest study to examine this
issue to date.19,20 In contrast, the adverse outcomes
resulting from malnutrition are clear, and this should be
the all-important consideration in the South African
situation. 
Protein-energy malnutrition and inflammation are
common in patients with chronic kidney disease and
worsen with progression toward end-stage renal
disease. These are major predictors of poor clinical
outcome, as reflected by the strong association
between hypoalbuminaemia and cardiovascular
disease. Among dialysis patients, traditional indicators
of overnutrition (high cholesterol or body mass index
(BMI)), which are deleterious in the general population,
are associated with better outcomes, while a low BMI
and low cholesterol or creatinine are risk factors for a
poor outcome. These paradoxical relationships between
nutritional markers and outcome are referred to as
‘reverse epidemiology’. 
In the Dialysis Outcomes and Practice Patterns Study
(DOPPS), which now includes the investigation of
patient profiles, therapies, practices and outcomes in
12 countries, nutrition-related parameters associated
with increased mortality included low BMI, low
subjective global assessment (SGA) score, and
hypoalbuminaemia. Mortality risk was increased 1.38
times with serum albumin levels below 35 g/l. In the US
patient cohort there was a 2.12-fold increase of the
relative risk of death for the lowest quartile (serum
albumin < 33 g/l) compared with the highest quartile 
(> 40 g/l).  A very simple modified SGA was used in
DOPPS, and correlated well with other nutritional
indices in different populations of patients and when
applied by health professionals from different countries
and cultures.19-21
It has been suggested that inflammation is the cause of
both malnutrition and CVD. The terms malnutrition-


















syndrome have been coined to indicate this interaction
and the important contribution of both of these
conditions to poor clinical outcome.22-24 Causes of
inflammation in dialysis patients include, among
others, exposure to dialysis membranes or peritoneal
dialysis fluid, poor water quality, peritonitis, and other
infections. More attention is now being focused on
nutritional or anti-inflammatory interventions, but so far
no randomised clinical trials have specifically examined
the effect of such interventions on malnutrition and
improved outcomes. It still remains unclear whether the
association with worse outcomes is related to
malnutrition at the time of initiation of dialysis or
whether it is secondary to changes in nutritional status
of ESRD patients over time.25 Clearly, a definite need
exists for outcomes research in CKD related to
nutrition, and secondly, for the effective
implementation of evidence-based guidelines where
these have already been established. 
There can be no doubt that the active participation of a
dietician is essential for any programme managing
patients with CKD. The K/DOQI guidelines, which have
been widely accepted, recommend that patients on
maintenance dialysis have monthly serum albumin and
creatinine measurements, and 6-monthly dietary
assessments by a qualified dietician.26 This includes a
subjective global assessment, and a dietary interview
which also reviews a 3-day dietary record. The DOPPS
survey found wide variability in the availability of a
renal dietician, from 20% in Spain to 85% in the UK.
The percentage of patients who had been counselled in
the previous 6 months varied from 7% (in Italy) to 75%
(in the UK).21
The survey by Herselman et al.27 in this issue of the
Journal found that while most South African dieticians
are following accepted guidelines, there is still
significant uncertainty about, and deviation from, best
practices.27 As this study was done in 2001, it would be
important to repeat it, especially with the growth in the
number of private dialysis centres. It is likely that as
more patients are being managed outside of the main
academic hospitals, they would be counselled by a
general dietician and not a specialist renal dietician.
Providing easy access to relevant nutritional guidelines
for dieticians and other interested parties is therefore
particularly important and in this light the paper by
Herselman and Esau on dietary exchange lists tailored
to the South African patient is a welcome addition.28
This information is available on the website of the
Nutrition Information Centre of the University of
Stellenbosch (http://www.sun.ac/nicus). Future
studies should examine not only whether South African
dieticians are implementing best practices, but also
look at the referral of patients with CKD and whether
nephrologists, physicians and providers of dialysis
services are making optimal use of the expertise of our
dieticians in their ongoing quest to improve the
outcomes of their patients.
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